J
John Cox
Researcher at University of Texas Southwestern Medical Center
Publications - 105
Citations - 5699
John Cox is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Health care & Politics. The author has an hindex of 21, co-authored 99 publications receiving 5402 citations. Previous affiliations of John Cox include University of Melbourne & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Leonard B. Saltz,John Cox,Charles D. Blanke,Lee S. Rosen,Louis Fehrenbacher,Malcolm J. Moore,Jean A. Maroun,Stephen P. Ackland,Paula K. Locker,Nicoletta Pirotta,Gary Elfring,Langdon L. Miller +11 more
TL;DR: In this paper, the authors compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of leucocil as first-line therapy for metastatic colorectal cancer.
Journal ArticleDOI
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
Paulo M. Hoff,Rafat Ansari,Gerald Batist,John Cox,Walter Kocha,Mario Kuperminc,Jean A. Maroun,David Walde,Charles Weaver,Evelyn Harrison,Hans U. Burger,Bruno Osterwalder,A. Wong,Ralf Wong +13 more
TL;DR: Oral capecitabine was more active than 5-FU/LV in the induction of objective tumor responses and demonstrated clinically meaningful benefits over bolus 5-fu/ LV in terms of tolerability.
Journal ArticleDOI
Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer
Thomas H. Cartwright,Allen Lee Cohn,Jerry A. Varkey,Yin-Miao Chen,Ted P. Szatrowski,John Cox,J. Schulz +6 more
TL;DR: Treatment with capecitabine resulted in clinically significant beneficial effects on tumor-related symptoms and yielded objective response activity in patients with metastatic or locally advanced pancreatic cancer.
Journal ArticleDOI
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
Mace L. Rothenberg,John Cox,Charles Butts,M. Navarro,Yung-Jue Bang,Rakesh Goel,Simon Gollins,L.L. Siu,S. Laguerre,David Cunningham +9 more
TL;DR: XELOX is noninferior to FOLFOX-4 when administered as second-line treatment in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy.
Journal ArticleDOI
Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease
TL;DR: It is suggested that alloimmunization and clinically apparent DHTRs occur more frequently in patients with sickle cell diseases and support pretransfusion testing for at least Rh and Kell red blood cell antigens in patients who are at high risk of such events.